Cargando…

Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report

Imatinib, a tyrosine kinase inhibitor has revolutionized the therapy of Philadelphia chromosome positive chronic myeloid leukemia. Side effects of imatinib include grade 1-4 hepatotoxicity in a subset of patients. We report the case of a 46-year-old male with chronic myeloid leukemia, who developed...

Descripción completa

Detalles Bibliográficos
Autores principales: Maiti, Baidehi, Setrakian, Sebouh, Daw, Hamed A
Formato: Texto
Lenguaje:English
Publicado: Cases Network Ltd 2009
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2740313/
https://www.ncbi.nlm.nih.gov/pubmed/19829996
http://dx.doi.org/10.1186/1757-1626-2-7526
_version_ 1782171704302239744
author Maiti, Baidehi
Setrakian, Sebouh
Daw, Hamed A
author_facet Maiti, Baidehi
Setrakian, Sebouh
Daw, Hamed A
author_sort Maiti, Baidehi
collection PubMed
description Imatinib, a tyrosine kinase inhibitor has revolutionized the therapy of Philadelphia chromosome positive chronic myeloid leukemia. Side effects of imatinib include grade 1-4 hepatotoxicity in a subset of patients. We report the case of a 46-year-old male with chronic myeloid leukemia, who developed hepatic hemosiderosis during treatment with imatinib. After ruling out the established congenital and acquired causes of hepatic hemosiderosis, we attribute this to a possible side effect of imatinib therapy. This condition was successfully treated with periodic phlebotomy thus precluding discontinuation of imatinib. To our knowledge, this is the first report of hepatic hemosiderosis most likely consequent to imatinib therapy.
format Text
id pubmed-2740313
institution National Center for Biotechnology Information
language English
publishDate 2009
publisher Cases Network Ltd
record_format MEDLINE/PubMed
spelling pubmed-27403132009-10-14 Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report Maiti, Baidehi Setrakian, Sebouh Daw, Hamed A Cases J Case report Imatinib, a tyrosine kinase inhibitor has revolutionized the therapy of Philadelphia chromosome positive chronic myeloid leukemia. Side effects of imatinib include grade 1-4 hepatotoxicity in a subset of patients. We report the case of a 46-year-old male with chronic myeloid leukemia, who developed hepatic hemosiderosis during treatment with imatinib. After ruling out the established congenital and acquired causes of hepatic hemosiderosis, we attribute this to a possible side effect of imatinib therapy. This condition was successfully treated with periodic phlebotomy thus precluding discontinuation of imatinib. To our knowledge, this is the first report of hepatic hemosiderosis most likely consequent to imatinib therapy. Cases Network Ltd 2009-05-26 /pmc/articles/PMC2740313/ /pubmed/19829996 http://dx.doi.org/10.1186/1757-1626-2-7526 Text en © 2009 Maiti et al.; licensee Cases Network Ltd. http://creativecommons.org/licenses/by/3.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
spellingShingle Case report
Maiti, Baidehi
Setrakian, Sebouh
Daw, Hamed A
Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report
title Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report
title_full Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report
title_fullStr Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report
title_full_unstemmed Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report
title_short Hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report
title_sort hepatic iron overload, a possible consequence of treatment with imatinib mesylate: a case report
topic Case report
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2740313/
https://www.ncbi.nlm.nih.gov/pubmed/19829996
http://dx.doi.org/10.1186/1757-1626-2-7526
work_keys_str_mv AT maitibaidehi hepaticironoverloadapossibleconsequenceoftreatmentwithimatinibmesylateacasereport
AT setrakiansebouh hepaticironoverloadapossibleconsequenceoftreatmentwithimatinibmesylateacasereport
AT dawhameda hepaticironoverloadapossibleconsequenceoftreatmentwithimatinibmesylateacasereport